LAG3 Expression in Triple Negative Breast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
AgeNot listed
SponsorSamsung Medical Center
About this trial
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Planned neoadjuvant chemotherapy
Triple negative breast cancer
Disqualifiers
HER2-positive breast cancer
Hormone receptor positive breast cancer
Trial design
Design model
Single group
Treatments tested in this trial
LAG-3 expression / immune checkpoint protein expression
Procedure/SurgeryEvaluate the tissue and blood before and after chemotherapy
Treatment groups
128 Participants
are divided into 1 treatment groupGroup A: LAG-3 expression/immune checkpoint protein expression evaluationExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
LAG-3 expression/immune checkpoint preotein expression
Relationship neoadjuvant chemotherapy plus immune checkpoint inhibitor
Time frame
Before chemotherapy, 1 weeks & 3 weeks after chemotherapy, curative surgerySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov